Exploiting the potential of P-selectin on the surface of megakaryocyte-derived exosomes to bind to CD44, which is highly expressed on the surface of GBM cells, we achieved precise active targeting to tumor cells (Supplementary Fig. 1). The gene discussed is CD44; the disease is neoplasm.